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Summary 
Stroke represents a major burden to patients and society, and resources spent on stroke research 
must be used efficiently and produce good value in terms of improvements in human health. 
However, there are many examples of poor value from stroke research funding, which result 
from the way in which stroke research has been chosen, designed, conducted, analysed, regulated, 
managed, disseminated, or reported. In a project including a survey and a symposium and 
involving stroke researchers in the European Stroke Organisation we have sought to identify 
sources of inefficiency and waste, recommended approaches to increase value, and highlighted 
examples of best practice in stroke research. Recent evidence suggests that progress has been 
made, but there is room for much improvement, and stroke researchers, funders and other 
stakeholders might consider our recommendations when planning new research.    
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Introduction 
The World Health Organisation has reported that stroke is the leading cause of disability among 
adults, and the second leading cause of death worldwide(1). More than 33 million people 
worldwide have a stroke each year(2), and in 2010 the estimated annual cost of stroke was $53.9 
billion in the US and €64.1 billion in Europe(3;4). Demographic changes caused by increase in 
longevity and changes in lifestyle will lead to a further increase in the burden of stroke(1;2), and 
research into prevention and treatment of stroke should therefore be a priority(5). Several notable 
successes in stroke research have delivered substantial health benefits in the past, with associated 
costs savings for society, for treatments such as antithrombotic or blood pressure lowering 
treatment for stroke prevention, and thrombolytic drugs, intra-arterial interventions, and 
multidisciplinary care in stroke units for treatment in the acute phase(6-10). However, despite 
recent modest increases in funding(5;11), stroke research remains underfunded compared to 
research in other major disease areas, such as cardiac disease and cancer(11;12). 
 
Given the limitations of resources it is all the more important that funding allocated to stroke 
research is used efficiently, and produces good value for money in terms of advances in 
knowledge or improvement in human health. A key challenge for funders of research is that 
much research does not lead to notable changes(13). It is to be expected that some projects will 
yield neutral or negative results, and some studies must be done with the sole intention of 
replicating previous research findings, but much research is wasteful or produces very little value 
for the financial, human or animal resources used. Waste and inefficiency may occur in the ways 
that biomedical research is chosen, designed, conducted, analysed, regulated, managed, 
disseminated or reported(13), and stroke research is no exception. Biomedical research typically 
involves many stakeholders, and researchers must navigate a complex environment of funders, 
regulators, academic research governance bodies, commercial clinical research organisations, 
industry, insurers, patient groups, publishers, and others. In stroke research, this complexity is 
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increased by the specific requirements of studies in prevention, acute care, and rehabilitation, 
with potential for waste and inefficiency. 
 
The Reduce research Waste And Reward Diligence (REWARD) Alliance(14), supported by a 
campaign launched by The Lancet(15), and a series of five papers(16-20), aims to increase value 
and reduce waste in biomedical research. The five papers produced specific recommendations 
and gave suggestions for monitoring of progress, aimed at funders, regulators, publishers, 
academic institutions, and researchers(16-20). In a satellite symposium at the ESO Conference in 
May 2016, arranged jointly by the ESO Trials Network Committee and The Lancet Neurology, 
stroke researchers, representatives from industry and publishers gathered with the aims to 
identify sources of waste, recommend approaches to increase the value of stroke research, and 
highlight examples of best practice (Panel 1). The symposium, which focussed on randomised-
controlled trials of treatments in clinical practice, was accompanied by a short survey among 
participants to inform the discussion, and used the structure of The Lancet series: research 
prioritisation; design, conduct and analysis; regulation and management; accessibility; and 
reporting(16-20). This Policy View summarises the symposium and survey conclusions. 
 
Panel 1. Aims of this Policy View 
 To identify sources of waste in the way stroke research is chosen, designed, conducted, 
analysed, regulated, managed, disseminated and reported 
 To suggest methods to reduce waste and increase value in each of these areas  
 To reinforce and encourage good practice and methodological research, by providing 
examples of best practice in stroke research 
 To encourage other disease-specific communities to seek evidence of waste in their own 
research and to seek ways to reduce it 
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Research prioritisation 
The financial and human resources available to undertake human health research are finitelimited. 
Therefore, to ensure best use of resources, regulators, funders, researchers and potential research 
participants should work collaboratively to identify priority areas for research(16). Many 
projects do not lead to notable benefits, either because they contribute little to knowledge about 
basic mechanisms that have relevance for human health (basic research), or to practice and 
policy (applied clinical research), or both (the “waste quadrant”)(16;21). Other projects 
contribute little because of unnecessary duplication of existing knowledge(16;21). 
 
An accepted criterion for prioritisation is that the research should address a health problem that 
causes a significant burden to society(21). However, resources allocated to stroke research are 
often not directed at yielding the greatest health benefits on a population level. For example, 
strategies for improved primary or secondary prevention (e.g. blood pressure lowering) are likely 
to yield large benefits at a population level, but are often not prioritised. Similarly, research into 
stroke recovery is consistently highly valued by patients and may have a large impact on stroke-
related disability, but few large rehabilitation trials have been performed. Several recent 
initiatives have sought to improve prioritisation of health research studies. The National 
Institutes of Neurological Disorders and Stroke (NINDS) are leading an effort to make trial 
selection more explicit and rationale in its Immediate Practice-Altering Clinical Trials (ImPACT) 
pilot program(22), and metrics for the public health impact of clinical trials have been 
developed(23). The James Lind Alliance(24) seeks to establish priority setting partnerships for a 
wide range of health problems, by bringing together stakeholders to identify the most important 
uncertainties. Of relevance to neurology, such partnerships have been established to set research 
priorities for cavernous malformations, dementia, multiple sclerosis, neuro-oncology, 
Parkinson’s disease, spinal cord injury, and stroke(25). 
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Another frequently cited criterion for priority setting is that the research should be patient-
centred, focussing on the aspects of the problem that people with the condition under study 
consider important. However, different stakeholders in research may have different priorities. 
For example, funding agencies may have selected a broad thematic area (e.g. cognitive decline 
after stroke), yet researchers may have a very narrow scientific question (e.g. whether a 
particular agent prevents cognitive decline), and potential research users may value studies that 
addresses clinical services rather than a specific drug therapy. Care givers may have yet another 
view(26), and, Iimportantly, even among patient sub-groups different priorities may exist.  For 
example, patients with stroke-related disability may be more interested in research into 
rehabilitation, while people who have not had a stroke, or a non-disabling stroke, may be more 
interested in research into prevention or acute treatment. Patients may also have different views 
on which outcomes are important. For example, while some will value the effect of a new 
treatment on cognitive function, others will prioritise social and emotional function, outcomes 
over the longer term, and risk of adverse reactions(27-29). To fulfil the criteria that research 
should address major health problems and the needs of patients, it seems clear that priority topics 
must be agreed through an alliance between stakeholders, including regulators, funders, 
researchers, care givers and patients(16).  
 
While some research aim at changing practice and policy (applied clinical research), other 
research can contribute to knowledge about basic mechanisms that have relevance for human 
health (basic research)(16;21), such as genetic mechanisms of stroke(30). There should also be a 
scientific basis for evaluating a specific clinical intervention. For example, it is possible that 
many of the neutral or negative trials of neuroprotective agents could have been avoided, had 
there been a better understanding of basic mechanisms, experimental bias, and the disparities 
between pre-clinical models and clinical studies(31-33), and a closer collaboration between pre-
clinical and clinical researchers. It is alsoFinally, it is a fundamental criterion for effective 
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research prioritisation that the question under study should not have been answered by prior 
research. It is therefore important that all research is preceded by a systematic review of what has 
already been done, to avoid unnecessary duplication, to identify what should be replicated, and 
to identify questions from previous work which could lead to new research(34). 
 
Research prioritisation exercises can themselves be wasteful of researcher time and effort. For 
example, although a specific EU “Horizon 2020” funding call will disburse half a dozen millions 
of Euros, only a few of the many applications will be funded(35). When the total cost in research 
time in preparing the applications is considered, a significant amount of non-productive resource 
is expended by those groups whose proposals were not funded. This raises the question whether 
projects should be triaged at an earlier stage, or whether there can be other ways of allocating 
funding, for example more sustained core funding over a defined period of time to particularly 
skilful research groups, to allow maximum freedom of research(36). 
 
Panel 2 gives examples of best prioritisation practice in stroke research. 
Panel 2. Examples of best prioritisation practice in stroke research 
1. Accessibility of information about completed, on-going and planned research. The 
Database of Research in Stroke (DORIS)(37) contains over 23,000 references to completed, 
ongoing and planned controlled clinical trials and systematic reviews collected by the 
Cochrane Stroke Group(38). It provides a rich source of information and can be used to 
identify research questions and to assess whether new research on a particular topic is called 
for or not. 
2. Use of systematic reviews to identify an important research topic.  A Cochrane systematic 
review of trials of selective serotonin reuptake inhibitor after stroke showed that a large 
number of small trials had been conducted, which, in aggregate, suggested that a large scale 
trial was needed(39). It was not feasible to obtain funding for a multinational trial, so a 
Policy View 
8 
 
“federation” of three parallel trials has been established(40), with an agreed core dataset to 
address mutually agreed questions. 
3. Involvement by stroke organisations. The World Stroke Organization recently collated 
publications on research prioritisation efforts in stroke. It highlighted the wide range of 
approaches that have been employed and how priorities differ(41). National and international 
stroke organisations can clearly play a facilitatory role in defining and setting priorities. 
 
Research design, conduct, and analysis 
Without appropriate design, conduct and analysis research is of reduced value, no matter how 
relevant the research question is, how efficiently the research is regulated, how widely the 
findings are disseminated, or how well they are reported(17). It is therefore important that 
research teams are able to draw on expertise appropriate to their tasks, at every stage of the 
research cycle. As Ronald Fisher said, “to call in the statistician after the experiment is done may 
be no more than asking him to perform a post-mortem examination: he can perhaps say what the 
experiment died of”. Because current incentives for biomedical researchers prioritise novelty and 
quantity over replication and quality, it is not enough simply to do work which is important and 
relevant. One must also be able to demonstrate that the work is of high quality. 
 
Poor experimental design, conduct and analysis are important causes of waste in stroke research. 
Pre-clinical research may be planned without input from clinical research, and clinical 
researchers may not have a proper understanding of what can be translated and what is lost in 
translation from pre-clinical studies(31-33). Eligibility criteria may be overly complex, for 
example relying on invasive or complex imaging studies, restricting the pool of available 
patients and centres and reducing generalisability. Data collection forms may also be complex, 
burdening centres with a requirement to collect data items which are subsequently never 
analysed or reported. Overly-optimistic assumptions may be made for sample size calculations, 
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leading to underpowered trials with inconclusive results. Important outcome measures may not 
be included at design phase, missing the opportunities to capture valuable information about 
quality of life, cognition, or costs of treatment. 
 
Institutions, funders and stroke organisations share the responsibility for education and training 
of stroke researchers, to enable them to design and conduct high-quality stroke research, 
including pre-clinical studies, translation research, and clinical trials specific for prevention, 
acute treatment, and recovery of stroke. Openly accessible resources could be developed 
(including, for example, standard contracts, outcome assessment instruments, trial insurance 
information). Investment should also be made into developing and maintaining stroke research 
networks, to facilitate and standardise stroke research within health care systems(42). 
 
Research institutions should also provide core methodological expertise. To ensure high quality, 
researchers need to have not only content expertise (e.g. a theoretical understanding of the 
statistical methods used), but also experience of the practical application of this knowledge in 
stroke studies. Problems may arise at the design phase if such expertise is not available, and 
recruiting individuals with such expertise after a grant has been awarded is challenging, since by 
that stage much of the study design is already established. Many research groups are funded 
largely through income from time-limited grants, so it is only possible to retain such experienced 
individuals if the lead researcher repeatedly applies for grants to sustain the group. This may 
divert effort from addressing the most relevant research questions, and so another perverse 
incentive is born. An alternative model would be that research institutions on a local or regional 
level provide funding for individuals with core research methodological expertise, either 
embedded within, or accessible to, the research groups that they serve. 
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Finally, it is important that publishers, funders, institutions and stroke organisations reward not 
only researchers who produce research outputs in large quantity or on novel topics, but also 
those who do research to replicate key research findings, or high quality studies of treatments in 
clinical practice with large impact on human health. While publishers and funding agencies have 
an important role (by limiting access to publications and grants), it is also critical that institutions 
adopt a more nuanced approach to selecting candidates for promotion or tenure, with emphasis 
on delivery of high quality, well-designed research (following for instance the Leiden 
Manifesto(43)), and that national research assessment exercises take greater account of the rigour 
with which research was conducted(44). There is also insufficient academic recognition of some 
key aspects of clinical research. For example, Data Monitoring Committees provide vital 
oversight of clinical trials, the members of such committees require a unique set of skills and 
experience and carry a great burden of responsibility, but such work does not attract academic 
recognition or reward(45). 
 
Panel 3 gives examples of good design, conduct, and analysis in stroke research. 
Panel 3. Examples of good design, conduct, and analysis in stroke research 
1. Quality of pre-clinical research. There has been greater attention to the rigour with which 
preclinical research is conducted and reported, mediated through the Stroke Therapy 
Academic Industry Roundtable (STAIR) initiative(31) and the publication of the Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines(46), with subsequent 
changes in editorial policy at Stroke, Journal of Cerebral  Blood Flow and Metabolism and 
International Journal of Stroke. Analysis of risk of bias in in-vivo research published in 
Stroke shows substantial improvements in the rates of reporting of, for instance, 
randomisation and blinding(47). 
2. Trial registration. There has been an increase in registration of stroke trials. Allowing a two 
year lag between study completion and publication, and looking only at stroke trials 
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registered at clinical trials.gov and only at studies indexed in PubMed, since 2000 there has 
been a 20-fold increase in the proportion of clinical trials registered (Malcolm R. Macleod, 
personal communication). 
3. Standardisation of conduct and analysis of stroke trials. The creation of clinical stroke 
research networks such as the National Institute for Health Research (NIHR) Stroke 
Research Network in the UK and StrokeNET in the US has led to standardisation and 
improvement in delivery of stroke trials (Gary A. Ford, personal communication). Progress 
has also been made in determining the most relevant outcome measures after stroke(48), 
including measures of cognitive function(49), and the best ways of analysing data from 
stroke trials(50). 
 
Regulation and management 
Research regulation (including governance) and management is essential to ensure that trials are 
performed ethically for the best interest and protection of participants, and to high scientific 
standards, but waste can arise from excessive and complex regulation and from poor 
management. Overburden of regulation and governance can lead to the failure of trials to recruit 
to time or target, or to researchers avoiding addressing important questions because of concerns 
that it will not be feasible to meet regulatory requirements, resulting in unnoticed and 
unquantifiable waste(18;51). 
 
Regulations for approval and conduct of research involving medical devices or drugs are 
complex, variably interpreted and enforced in different countries, and often out of proportion to 
the risk to participants(52). For instance, the EuroHYP-1 study of therapeutic hypothermia for 
acute ischaemic stroke(53) has been subject to extensive delay in receiving regulatory approval, 
due to being inconsistently classified as a drug trial, a device trial, neither or both, across 
different competent authorities in Europe. Some of the regulations for drug trials, such as 
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expedited reporting of suspected unexpected serious adverse reactions, and on-site monitoring, 
were developed for the testing of new agents in industry-led studies, and may not be appropriate 
for low-risk investigator-led trials testing licensed agents that have been in everyday clinical use 
for many years. 
 
Regulations for recruitment of patients with reduced consent capacity represent a particular 
problem in acute stroke trials, in some cases leading to delays in recruitment because of 
burdensome consent processes. There is a need to find alternative and simpler ways of patient 
recruitment to low-risk acute stroke trials. For example, some trials have developed emergency 
consent processes, with brief(54) or verbal consent(55;56), or even waiver of consent(57), after 
approval by ethics committees. The European Commission’s revised proposal for clinical trial 
regulation opens for a more flexible approach to consent in emergency settings(58), and this 
should probably be used more often in stroke research. 
 
Reduction in waste can also be expected from recent initiatives aiming at simplifying, 
centralising and harmonising regulation, and at making it proportionate to the degree of risk 
posed by the intervention under study. For example, the revised Declaration of Helsinki and the 
revised proposal for clinical trial regulation in the EU(58) state that the level of trial monitoring 
should be proportionate to the potential harms to research participants, and the Voluntary 
Harmonisation Procedure makes it possible to seek national approval simultaneously from several EU 
member states(59). Centralisation of research ethics committees has also taken place in many 
countries, but other initiatives have had less impact, such as the European Network of Research 
Ethics Committees (EUREC)(60), which was formed to foster a coordinated ethics review 
infrastructure in Europe. The MoreTrials campaign(61) represents a group of trialists lobbying 
for a revision of the International Conference on Harmonisation Good Clinical Practice (ICH-
GCP) guidelines which will make trials simpler, quicker and cheaper to run. For example, risk 
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adaptive monitoring and data verification processes can reduce monitoring costs without 
impacting on patient safety(62). The most recent addendum has gone some way to achieving 
this(63). 
 
Waste can be further reduced if regulators, policy makers and health care funders can play an 
active role in supporting research, for example by facilitating the integration of research into 
everyday clinical practice. Funding can be used as an incentive for institutions to take part in 
research, and re-imbursement of new, expensive treatments can be reserved for treatment that are 
given within a trial, as was done in the Multicenter Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial of intra-arterial 
treatment for acute ischaemic stroke(64). Integration of research in clinical practice can also be 
facilitated through establishment of research networks within the health care system, although 
this has not been scientifically evaluated. The NIHR Stroke Research Network has streamlined 
research delivery and fostered a collaborative and constructively competitive environment in the 
UK(18), and in the US the establishment of StrokeNet was seen as a step in improving both 
research and clinical stroke care(65). Recruitment into randomised-controlled trials may also be 
increased by allowing co-enrolment to take place under special circumstances(66), or by 
allowing randomisation of patients who have already been included in stroke registries, as is 
planned in the TIMING study of the optimal timing of anticoagulation after stroke among 
patients with atrial fibrillation(67). 
 
Inefficient trial management is another source of waste, which can lead to slow recruitment and 
poor retention of patients in clinical trials(68), as well as low data quality. There is some 
evidence from methodological research for the effect of interventions aiming at increasing 
patient recruitment and retention in trials(68), and the Trial Forge(69) and Prioritising 
Recruitment in Randomised Controlled Trials (PRioRiTy)(70) initiatives aim at increasing 
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efficiency of trial management. Other initiatives are advocating methodological research to find 
better ways of recruiting and retaining patients, for example by conducting randomised-
controlled trials embedded within an on-going trial (host trial), a so-called Study Within A Trial 
(SWAT)(71-73). The SWAT Store is a central repository of ongoing SWATs, which allows 
investigators to see what methods are currently being tested(74). 
 
Panel 4 shows examples of best practice in regulation and management of stroke research. 
Panel 4. Examples of best practice in regulation and management of stroke research 
1. Integration of research in clinical practice: Trials within registries, and reimbursement of 
cost of new, unproven treatments only within a trial. Patients with stroke and atrial 
fibrillation included in the Swedish Stroke Registry are simultaneously included into the 
randomised-controlled TIMING trial of early vs. deferred start of anticoagulant therapy(67). 
During most of the course of the MR CLEAN trial of intra-arterial treatment for acute 
ischaemic stroke, the costs of treatment were only reimbursed for patients included into the 
trial(64), which was important for the trial’s ability to deliver to time and target. 
2. Use of alternative information and consent procedures, and alternative methods for site 
initiation and management. The Tranexamic acid for IntraCerebral Haemorrhage (TICH-2) 
trial uses a simple abbreviated one-page patient information sheet in order to effectively gain 
consent in an emergency situation(54). The Paramedic Initiated Lisinopril For Acute Stroke 
Treatment (PILFAST) trial(55) and the Rapid Intervention with Glyceryl trinitrate in 
Hypertensive stroke Trial 2 (RIGHT-2)(56) used verbal consent in the pre-hospital setting. 
The Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage (ULTRA) trial of 
tranexamic acid for subarachnoid haemorrhage allows waiver of consent(57), as did some of 
the trials of intra-arterial treatment. Remote site initiation and monitoring has been used in 
many stroke trials(54;75-77) as a more cost-effective alternative to face-to-face visits.   
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3. Research on methods to improve recruitment and retention in stroke studies: Study-
Within-A-Trial (SWAT). The ESO Trials Network Committee has addressed regulation and 
management in previous workshops(52;68), and the REstart or STop Antithrombotics 
Randomised Trial (RESTART)(78) is delivering on these workshops by testing an alternative 
method for patient recruitment in a SWAT(79). 
 
Accessibility of information 
Much research never gets published(20;80), and access is restricted to subscribing institutions for 
many of the journal reports that are published. Furthermore, journal reports represent only a 
fraction of the information from a study, and the selection of which studies to report, and what 
information to share from each study, is often biased. Valuable information is also contained in 
research protocols, and more detailed analysis of participant-level data can be of great value, to 
verify the original findings, to answer new questions, or to plan new research. Accessibility of 
research protocols, primary journal reports, full study reports and availability of individual 
participant data will therefore increase value of research, and can reduce waste by avoiding 
redundant, misguided or even harmful research being done(19). 
 
Investigators report that limited time and low priority or importance of results are the most 
common reasons for not reporting studies(81). At the same time there is no empirical evidence 
that journals preferentially publish reports showing positive results(81), so there are reasons to 
believe that publication bias is mostly due to investigators’ selective reporting. It was therefore 
an important step in the right direction when the International Committee of Medical Journal 
Editors (ICMJE) in 2005 required prospective registration of all trials as a condition for 
publication of a primary study report. This year the US Department of Health and Human 
Services and the US National Institutes of Health have gone further by issuing rules for 
registering of clinical trials and submission of summary results to ClinicalTrials.gov(82). A next, 
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natural step could be for funders to withhold a part of the grant until the research is published, as 
practiced by the NIHR Health Technology Assessment programme in the UK. At the same time, 
research institutions could develop methods for rewarding full dissemination of research. 
 
Trials produce many more data than presented in a single article, and data selected for 
presentation in the primary report can be biased. For example, the study protocol and the 
statistical analysis plan contain data that are essential to the correct interpretation of the trial’s 
results. Unexpected challenges can arise, and plans often need to be changed for good reasons 
(e.g. change in inclusion criteria, change in sample size requirements due to unexpected outcome 
event rates, change in analysis method), but such changes need to be apparent rather than hidden. 
However, study protocols and statistical analysis plans are often not generally accessible, and 
when these can be accessed, even items as critical as eligibility criteria for inclusion into the trial 
were found to differ frequently between the study protocol and the published article(83;84). Such 
selective reporting can amplify the bias arising from selective reporting of entire studies(19), and 
is a possible explanation why the results often cannot be independently replicated. Suspicion of 
selective reporting can also be a reason for distrust in trial results, even for treatments of which 
benefits are considered beyond  reasonable doubt by the majority of clinicians, such as 
thrombolysis for acute ischaemic stroke(85). One solution could be to require the publication of 
the study protocol after registration(83;84) or, if this is not feasible, through registration at for 
example the Open Science Framework(86). 
 
Even when studies are reported, access to research is restricted, due to costs of journal 
subscriptions, or language barriers. “Open access” publishing represents a step forward, but is 
still not widely used(87), probably because of the extra costs for research institutions and 
individual researchers, and because most open access journals do not yet have comparably high 
impact factors. 
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The problem of reporting bias can perhaps be reduced by mandating the sharing of individual 
participant data from clinical trials, as proposed by the ICMJE and increasingly demanded by 
research funders and publishers(19;88;89). Data sharing will allow verification of the published 
results and detection of errors(19), which can increase confidence in results. It can also be used 
to examine new research questions, particularly if data from different trials can be pooled, and to 
plan new trials, for example in sample size calculations.  
 
Obviously, specific conditions must be met to support the widespread sharing of individual 
participant data(88;90). Participants’ anonymity must be preserved, and investigators should 
receive academic credit for sharing their data, from funders, publishers and institutions. They 
should also have the opportunity to publish any pre-specified analyses before giving access to 
others, and they should be included in publications arising from analysis of data that they have 
collected(91). It is also important that data is collected in standard formats to allow their 
integration, and that data are accompanied by clear metadata to avoid misinterpretation. There is 
also a need for standardised repositories where data can be uploaded and curated, such as the 
Virtual International Stroke Trials Archive (VISTA)(92;93). 
 
There are several initiatives aiming at making research information available. The AllTrials 
campaign has proposed that “all trials past and present should be registered, and the full methods 
and the results reported”(94). The Linked Clinical Trial project(95) is an independent 
membership association, founded and directed by publishers, that connects users to all published 
material related to an individual clinical trial. ClinicalTrials.gov also allows for links to protocols 
and full study reports, including data that were not included in the published report(96). Center 
for Open Science allows researchers to organise and archive research material and data, and later 
make these publicly available(97). Finally, the Academic Research Organization Consortium for 
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Continuing Evaluation of Scientific Studies — Cardiovascular (ACCESS CV) aims to provide 
avenues for sharing data from cardiovascular clinical trials(98). 
 
Panel 5 shows examples of best data sharing practice in stroke research. 
Panel 5. Examples of best data sharing practice in stroke research 
1. Repository for individual participant data. The Virtual International Stroke Trials Archive 
(VISTA)(92) has collated anonymous data from clinical trials and provided access to 
researchers for novel exploratory analyses for more than 10 years, and currently contains 
data from more than 82,000 patients.  
2. Pooling of individual participant data. Pooled analyses of individual participant data from 
trials of carotid endarterectomy for symptomatic carotid artery stenosis(99;100), carotid 
endarterectomy versus stenting(101), surgical decompression of space-occupying 
hemispheric infarction(102), thrombolytic treatment(103), and intra-arterial treatment for 
acute ischaemic stroke(104) have been able to estimate treatment effects in specific subsets 
of patients. The sharing of individual participant data before the publication of the results of 
the individual trials has allowed much earlier identification of benefit of surgical 
decompression in patients with space-occupying hemispheric infarction than would have 
been possible with each of the trials alone(102). 
3. “Threaded publications” and publication of full datasets. The Third International Stroke 
Trial (IST-3)(105) was given the BioMed Central Open Data Award in 2012 for excellence 
in sharing, standardisation, publication and re-use of biomedical research data, by linking 
“threaded publications” to create a “thread of evidence”(106). The NINDS trial(107) and the 
First IST(108) datasets are made freely available on-line, and the IST-3 dataset is now also 
available to bona fide researchers. 
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Reporting 
Few would dispute that reports of research should describe the question, its importance, the 
experimental method, the results, and the meaning of the results(109). Research will be wasteful 
if information is inadequate to be able to interpret the results correctly, to plan new research 
based on what has already been done, and to replicate research. Reporting guidelines aim to 
improve the quality of research reports, but they are often not adhered to. Many studies have 
found substantial evidence of poor research reporting, for all objectives listed above, regardless 
of disease, type of study, and type of publication(20). 
 
Adequate reports of research should clearly describe which questions were addressed and why, 
what was done, what was shown, and what the findings mean. Although the investigation of the 
quality of reporting in stroke research has not been extensive, there is evidence of: publication 
bias among pre-clinical stroke studies(110), clinical randomised-controlled trials(20;111) and 
observational studies(112); inadequate adherence to reporting criteria among randomised-
controlled trials(113); and insufficient descriptions of interventions in trials included in 
systematic reviews(114). However, it has yet to be establish the extent of adherence to reporting 
guidelines, the adequacy of reporting of pharmacological interventions, the selectiveness of 
outcome reporting(115), and the reproducibility of findings in stroke research. 
 
Reporting guidelines exists for protocols for some research designs (including the Standard 
Protocol Items: Recommendations for Interventional Trials (SPIRIT) guideline for clinical trial 
protocols(116)), but reporting guidelines for stroke trial protocols may also need to be specific to 
trials of prevention, acute treatment and rehabilitation. Stroke organisations could take on the 
task of writing guidelines for stroke trial protocols, or for elements of such protocols, for 
example outcome definitions. 
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A major initiative that arose to address some of the systemic problems with reporting in 
biomedical research was the Enhancing the QUAlity and Transparency Of health Research 
(EQUATOR) network(20;117). EQUATOR includes a comprehensive searchable library of 
reporting guidelines (e.g. CONSORT, PRISMA, STROBE, STARD, ARRIVE), toolkits to 
facilitate good reporting, and training courses. These reporting guidelines are not just a resource 
for researchers, but also for teachers, peer reviewers, and journal editors. For example, the 
Consolidated Standards of Reporting Trials (CONSORT)(118) and most other reporting 
guidelines recommend that research reports should set their findings in the context of an updated 
systematic review of all the available evidence. However, journals can still do more to endorse 
and enforce the use of reporting guidelines, such as CONSORT(119), including the 
recommendation to include updated systematic reviews. 
 
The Lancet has set an example by requiring, since 2005, clinical trials to be reported in the 
context of all the available evidence(120), requiring a Research in Context panel in which the 
authors report any research in the context of an up-to-date systematic review since 2010(121), 
and requiring the added value of the research to be described in a more prominent panel since 
2014(122). The Lancet’s series also recommended several actions to resolve and monitor the 
problems with research reporting(20): Funders and research institutions were encouraged to take 
responsibility for providing an infrastructure that facilitates good reporting, as well as to regulate 
and reward research so that it is well reported, and publishers should join funders and institutions 
in improving the capability and capacity of authors and reviewers to support good reporting. 
 
Some examples of best practice in research reporting exist in stroke research (Panel 6). We hope 
that these examples will motivate good practice as well as systematic evaluations of the 
adequacy of reporting of stroke research. 
Panel 6. Examples of good reporting practice in stroke research 
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1. Reporting guidelines for rehabilitation journals. A collaborative initiative between 28 
rehabilitation and disability journals has arisen to adopt reporting guidelines(123). 
2. Adherence to reporting guidelines in stroke journals. The European Stroke Journal requires 
authors to submit a checklist to demonstrate adherence to the relevant reporting 
guideline(124). 
3. Use of the Template for Intervention Description and Replication (TIDieR) checklist. The 
TIDieR checklist, intended to improve the reporting of interventions(125), has already been 
used in a trial of functional strength straining after stroke(126). 
 
Conclusions and future perspectives 
In this Policy View we have identified sources of waste in stroke research, and recommended 
approaches to reduce waste and increase value for each of the areas covered by The Lancet’s 
series (Panel 7). Our examples of best practice illustrate that some progress has been made, but 
there is room for much improvement, and stroke researchers, funders and other stakeholders 
might consider our recommendations when planning new research. 
 
For some of the areas (e.g. research design, accessibility and reporting) there is consensus on 
what constitutes best practice, and what changes to practice and policy that might reduce waste. 
However, little empirical evidence exists about adherence to these practices. For example, 
although reporting guidelines have been made, we have no data on whether they are used for 
reporting of stroke studies. For other areas (e.g. research regulation, management and analysis) 
there is uncertainty about what is best practice, and consensus has yet to be reached. For example, 
there is still many questions about the best ways to increase patient recruitment and retention(68), 
and to analyse data from stroke trials(50). In order to understand what is best practice in these 
areas, and to learn whether best practices are followed, we need more methodological research. 
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Approaches to reduce waste and increase value in stroke research must therefore include changes 
to practice as well as methodological research. 
 
For the areas in which there is consensus, waste must be reduced by changes to practice, for 
example, stronger adherence to reporting guidelines. Just as integration of research findings into 
clinical practice is often slow (e.g. proven treatments), adherence to best practices in stroke 
research can be inadequate. Information about adherence is important, but may not be sufficient, 
and stroke research may benefit from the results of implementation science to foster this last, 
important step from consensus to change in research practice. 
 
We have highlighted examples of best practice in stroke research in the hope that they will 
encourage stroke researchers to seek collaboration with each other, with other stakeholders, and 
with researchers in other disease-specific areas. The REWARD Alliance brings together 
researchers and other stakeholders in all areas of biomedical research, and can be one way of 
reducing waste. The REWARD Alliance and The Lancet series have already had many 
impacts(127), the first REWARD Alliance conference took place together with the EQUATOR 
Network in 2015, and REWARD symposia have taken place at the Clinical Trials in Alzheimer’s 
Disease (CTAD) conference in 2015 and now at the ESO Conference in 2016. Stroke researchers 
and clinicians can join by signing up to the REWARD statement(128), encouraging their 
organisations to add their name to the other partners of The Lancet’s REWARD campaign(15), 
conducting research to investigate the existence, causes, and solutions to waste, and – most of all 
– scrutinising their own practice. 
 
Panel 7. Take-home messages 
 There is waste and reduced efficiency in the way stroke research is chosen, designed, 
conducted, analysed, regulated, managed, disseminated and reported. There is need for 
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change in practice, as well as for methodological research to investigate methods of reducing 
waste and to monitor whether known methods of reducing waste are being followed. 
 Prioritisation: Criteria for prioritisation and priority topics for stroke research should be 
agreed through an alliance between stakeholders, including professional and patient/carer 
stroke organisations. All projects should be able to demonstrate that they have considered the 
needs of users of research, and that they build on knowledge from previous research. 
 Design, conduct and analysis: Institutions should provide education and training in research 
methods, and core methodological expertise. Funders should consider investing in stroke 
research networks, and funders, publishers and institutions should reward replication and 
quality of stroke research (instead of quantity alone). Stroke researchers might consider 
developing specific recommendations for the conduct of clinical trials in prevention, acute 
treatment, and recovery of stroke. Metrics could be used to check compliance with 
recommendations. Methodological research should be done to monitor the degree to which 
recommendations are followed, and to find the best research methods. 
 Regulation and management: Regulators and researchers should work together to simplify, 
centralise and harmonise regulations, and make them proportionate to the potential harms to 
participants. Researchers and regulators should consider simpler consent procedures and 
waiver of consent in the acute phase of stroke, and work together with health service funders 
to facilitate the integration of research in everyday clinical practice. Researchers should 
perform methodological research, for example to find the best methods for increasing patient 
recruitment and retention. 
 Dissemination: All research protocols and statistical analysis plans should be published or at 
least registered. Funders and institutions should support stroke researchers to publish their 
research with open access, and might consider allocating a part of the grant for publication 
and wider dissemination. Institutions and researchers should be willing to share individual 
participant data, and studies should be planned in advance to combine data. Researchers and 
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regulators should work together to solve issues relating to protection of participant 
anonymity and rights of investigators. 
 Reporting: Researchers and publishers might consider developing reporting 
recommendations for stroke trials that are specific to trials of prevention, acute treatment and 
rehabilitation. Metrics could be used to assess adherence to recommendations. Institutions 
and funders should reward adherence to reporting recommendations, as well as full and 
prompt reporting. Publishers should do more to endorse and enforce the use of reporting 
guidelines, including the recommendation to include updated literature reviews 
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Search strategy and selection criteria 
References for this Policy View were suggested by members of the ESO Trials Network 
Committee. Further references were identified through searches on PubMed with the terms 
“waste”, “inefficiency”, “prioritisation”, “design”, “conduct”, “analysis”, “regulation”, 
“management”, “accessibility” OR “reporting”, each in combination with “stroke” AND 
“research”. Only papers published in the period January 2010 to August 2016 were considered. 
The symposium was based on The Lancet series(16-20), and topics and speakers were agreed 
between the ESO Trials Network Committee and The Lancet Neurology editors. The survey was 
designed by members of the ESO Trials Network Committee. 
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